SCHEMBL7238992

SCHEMBL7238992

Cc1ccnc(-c2ccc(C3OCCO3)c([N+](=O)[O-])c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
MEN1 O00255 1/20 0.36
S1PR4 O95977 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
PABPC1 P11940 1/20 0.36
S1PR1 P21453 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ABL1 P00519 4/20 0.35
BCR P11274 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7237198 0.85 CCR1 (0.41) CCR1CCR5CCR8MAPTRAB9A
SCHEMBL7236715 0.78 MAPT (0.52) CYP2A6CCR1CCR5CCR8MAPT
SCHEMBL20328777 0.75 TSHR (0.53) MAPTHTTKMT2AALDH1A1CYP3A4
SCHEMBL7235982 0.74 ALDH1A1 (0.54) MAPTRAB9ANPC1MEN1LMNA
SCHEMBL7229501 0.74 CYP2A6 (0.42) CYP2A6CCR1CCR5CCR8MAPT
SCHEMBL11166231 0.70 ALDH1A1 (0.52) CYP2A6CCR1CCR5CCR8MAPT
SCHEMBL14253769 0.70 MEN1 (0.49) MAPTMEN1LMNAGAAKMT2A
SCHEMBL30469276 0.70 MAPT (0.59) CYP2A6MAPTRAB9ANPC1ALDH1A1
SCHEMBL7237866 0.70 MAPT (0.59) CYP2A6MAPTRAB9ANPC1ALDH1A1
SCHEMBL25385922 0.69 S100A4 (0.41) MAPTRAB9AMEN1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed